
Commit Biologics brings seed financing to $60 million for complement-powered medicines
Laboratory photograph: Commit Biologics, from its official financing announcement.Commit Biologics has announced the final close of a $60 million (€54 million) seed financing round to move its complement-powered immune engagers toward human trials. The final close was led by Ackermans & van Haaren, with new investors AbbVie Ventures and M Ventures joining existing backers Bioqube Ventures, Korys and Novo Holdings.
The $60 million is the completed seed-round total, not a separately disclosed new cheque of that size. The Danish company previously announced €16 million in seed funding in May 2024. Its November 17 announcement does not separately state how much capital is newly added in this final close.
Commit's BiCE platform engineers antibodies to bind a target on a diseased cell and recruit C1q, a protein that activates the complement part of the immune system. It is a different approach to immune cell killing from treatments that depend on T cells. The company is developing these molecules for cancer and autoimmune diseases.
The financing will support studies and a regulatory filing intended to enable clinical development of COM002, its first nominated candidate. Commit also plans to advance a second program into IND-enabling development and expand its pipeline. COM002 initially targets relapsed or refractory non-Hodgkin lymphoma, with possible later autoimmune applications, according to the company's November 12 update.
Commit says its platform has produced targeted B-cell depletion in non-human-primate studies. Those results are preclinical and company-reported, not evidence of safety or benefit in patients. The company expects first patient dosing in early 2028; that is a development target, not a trial already underway or an approved treatment.
An Aarhus University spin-out, Commit is led by CEO Thomas L. F. Montgomery Andresen. The financing adds representatives of AbbVie Ventures, M Ventures and Ackermans & van Haaren to its board.
Financing total, six named investors and use of funds: official Commit Biologics announcement, 17 November 2026. COM002 and early-2028 target: official 12 November update. Earlier seed: official 9 May 2024 announcement. Technical and preclinical results are company-reported, not demonstrated patient benefit. No separate incremental final-close amount or valuation is disclosed.
Additional reporting
Engineers antibodies that recruit the complement protein C1q to target diseased cells independently of T cells.
Final close brings total seed financing to $60 million (€54 million); incremental new capital is not separately disclosed.
Ackermans & van Haaren, AbbVie Ventures, M Ventures, Bioqube Ventures, Korys, Novo Holdings.
Complete IND-enabling work and filing for COM002, advance a second program and expand the BiCE pipeline.
Denmark; an Aarhus University spin-out.
Preclinical company-reported results. Human safety and benefit are not established; first patient dosing is targeted for early 2028.